Transport kinetics of leucine enkephalin across Caco-2 monolayers: Quantitative analysis for contribution of enzymatic and transport barrier

被引:22
作者
Quan, YS [1 ]
Fujita, T [1 ]
Tohara, D [1 ]
Tsuji, M [1 ]
Kohyama, M [1 ]
Yamamoto, A [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan
关键词
aminopeptidases; protease inhibitors; leucine enkephalin; transport; clearance; Caco-2 cell monolayers;
D O I
10.1016/S0024-3205(99)00056-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In this study, we determined the activities of four aminopeptidases such as aminopeptidase B (APB), M (APM), N (APN) and dipeptidylpeptidase IV (DPP IV) in Caco-2 cells and compared with those in the rat intestinal mucosae. The activities of APE, APM and APN appeared to be highest in rat small intestinal mucosa, while DPP N activity was much higher in Caco-2 cells than that in the rat intestinal mucosa. Next the inhibitory effects of various protease inhibitors were examined in Caco-2 homogenate. Three tested inhibitors, bacitracin, amastatin and puromycin, effectively inhibited the activities of APM, APN and DPP IV except for APE. Further, we quantitatively evaluated the permeation and degradation properties of leucine enkephalin (Leu-Enk) in the presence or absence of inhibitors in Caco-2 monolayer system. Leu-Enk had a high degradation clearance (CLd) and a low permeation clearance (CLp) in Caco-2 monolayers. This finding indicates that the very rapid degradation of Leu-Enk on the apical side of Caco-2 monolayers was due to aminopeptidases. However, these protease inhibitors besides sodium glycocholate were able to reduce the CLd values markedly, thereby increasing the permeation amount of Leu-Enk across Caco-2 monolayers. In particular, amastatin significantly decreased the CLd value and increased the CLp value. This enhanced CLp value was further increased by the coadministration with an absorption enhancer, EDTA or laurylmaltoside. These findings are relevant to the oral administration of peptide drugs and to developing an efficient oral delivery system.
引用
收藏
页码:1243 / 1252
页数:10
相关论文
共 21 条
[1]   ABSORPTION CHARACTERISTICS OF CHEMICALLY MODIFIED-INSULIN DERIVATIVES WITH VARIOUS FATTY-ACIDS IN THE SMALL AND LARGE-INTESTINE [J].
ASADA, H ;
DOUEN, T ;
WAKI, M ;
ADACHI, S ;
FUJITA, T ;
YAMAMATO, A ;
MURANISHI, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (06) :682-687
[2]   Targeting of peptide and protein drugs to specific sites in the oral route [J].
Bai, JPF ;
Chang, LL ;
Guo, JH .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04) :339-371
[3]   COMMON CHARACTERISTICS FOR NA+-DEPENDENT SUGAR-TRANSPORT IN CACO-2 CELLS AND HUMAN-FETAL COLON [J].
BLAIS, A ;
BISSONNETTE, P ;
BERTELOOT, A .
JOURNAL OF MEMBRANE BIOLOGY, 1987, 99 (02) :113-125
[4]   EXPRESSION AND PROTEIN-KINASE C-DEPENDENT REGULATION OF PEPTIDE/H+ COTRANSPORT SYSTEM IN THE CACO-2 HUMAN COLON-CARCINOMA CELL-LINE [J].
BRANDSCH, M ;
MIYAMOTO, Y ;
GANAPATHY, V ;
LEIBACH, FH .
BIOCHEMICAL JOURNAL, 1994, 299 :253-260
[5]   Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: Comparison between acylation and application of protease inhibitors [J].
Fujita, T ;
Kawahara, I ;
Quan, YS ;
Hattori, K ;
Takenaka, K ;
Muranishi, S ;
Yamamoto, A .
PHARMACEUTICAL RESEARCH, 1998, 15 (09) :1387-1392
[6]   IMPROVEMENT OF LARGE INTESTINAL-ABSORPTION OF INSULIN BY CHEMICAL MODIFICATION WITH PALMITIC ACID IN RATS [J].
HASHIZUME, M ;
DOUEN, T ;
MURAKAMI, M ;
YAMAMOTO, A ;
TAKADA, K ;
MURANISHI, S .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (07) :555-559
[7]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736
[8]   TRANSPORT OF A LARGE NEUTRAL AMINO-ACID (PHENYLALANINE) IN A HUMAN INTESTINAL EPITHELIAL-CELL LINE - CACO-2 [J].
HIDALGO, IJ ;
BORCHARDT, RT .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1028 (01) :25-30
[9]   A SURVEY OF MEMBRANE PEPTIDASES IN 2 HUMAN COLONIC CELL-LINES, CACO-2 AND HT-29 [J].
HOWELL, S ;
KENNY, AJ ;
TURNER, AJ .
BIOCHEMICAL JOURNAL, 1992, 284 :595-601
[10]  
JIYANG LL, 1993, GENOMICS, V17, P657